Medtronic’s Extravascular ICD Hits Targets In Trial; Will Soon Compete With Boston Scientific’s S-ICD
Executive Summary
Results from the pivotal trial of Medtronic’s EV ICD extravascular ICD, presented at the European Society of Cardiology congress in Barcelona, imply that Medtronic will be able to launch the device in Europe by the end of this year and in the US in 2023.
You may also be interested in...
FDA Approves Medtronic’s 'Extra-Vascular' ICD, The First Of Its Kind
The Aurora EV ICD system provides anti-tachycardia pacing, cardioversion and defibrillation therapies through a lead placed under the breastbone, outside of the heart and veins.
Long-Term Data Affirm Durability Of Medtronic’s EV-ICD
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition is an update on Medtronic's Extravascular ICD (EV-ICD).
Cardio Catch-Up: Two Studies Support Boston Scientific’s Subcutaneous ICD
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition covers the two clinical studies of Boston Scientific's Emblem MRI subcutaneous implantable cardioverter defibrillator.